Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Advertisement
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

US FDA Biosimilar Guidance Update Will Relax Interchangeability Standards

Updated interchangeability guidance is one of several 'incremental reforms' agency is working on that could ease development burden for biosimilars, Commissioner Scott Gottlieb says.

Biosimilars Drug Approval Standards

Off-Label Communications: US FDA Won't Impede Discussions With Payers, Gottlieb Says

Guidance, to be issued 'very soon,' will provide a safe harbor for discussions between manufacturers and payers about off-label drug uses, Commissioner Scott Gottlieb says.
Regulation FDA

PBMs Offering Prescribers Real Time Visibility On Cost-Sharing, Cheaper Alternatives

CVS Health and OptumRx join Express Scripts in offering programs to enhance transparency around prescription drug cost sharing, reinforcing the impact of formulary placement.
Pricing Strategies Pharmacy Benefit Management

Trump's Drug Pricing Plans On Slow Walk? HHS To Solicit Comment On Policies

No big policy implementation expected to be announced during president's speech planned for next week. HHS will continue to gather feedback on various approaches to lowering drug pricing.

Pricing Debate Medicare

New Migraine Drugs May Not Be Cost Effective In Patients With Other Options, ICER Suggests

Draft cost effectiveness report released by the Institute for Clinical and Economic Review uses $8,500 annual cost for Aimovig and fremanezumab as a "placeholder" price.

United States Cost Effectiveness

ICER To Open Cost Effectiveness Models To Drug Firms During Review Process

Institute for Clinical and Economic Review launching pilot program that allows drug assessment models  to be inspected, but not manipulated, by manufacturers.
Pricing Debate Policy
See All
Advertisement
UsernamePublicRestriction

Register